These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19710077)

  • 1. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.
    Anderson PL; Aquilante CL; Gardner EM; Predhomme J; McDaneld P; Bushman LR; Zheng JH; Ray M; MaWhinney S
    J Antimicrob Chemother; 2009 Nov; 64(5):1071-9. PubMed ID: 19710077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.
    Wempe MF; Anderson PL
    Drug Metab Dispos; 2011 Mar; 39(3):522-7. PubMed ID: 21148251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
    Dickinson L; Boffito M; Back D; Waters L; Else L; Davies G; Khoo S; Pozniak A; Aarons L
    J Antimicrob Chemother; 2009 Jun; 63(6):1233-43. PubMed ID: 19329800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
    Estévez JA; Moltó J; Tuneu L; Cedeño S; Antonijoan RM; Mangues MA; Clotet B; Domingo P; Puntes M; Barbanoj MJ; Valle M
    J Antimicrob Chemother; 2012 Aug; 67(8):2013-9. PubMed ID: 22566588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
    Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
    J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
    Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
    Venuto CS; Mollan K; Ma Q; Daar ES; Sax PE; Fischl M; Collier AC; Smith KY; Tierney C; Morse GD
    J Antimicrob Chemother; 2014 Dec; 69(12):3300-10. PubMed ID: 25159623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Johnson DH; Venuto C; Ritchie MD; Morse GD; Daar ES; McLaren PJ; Haas DW
    Pharmacogenet Genomics; 2014 Apr; 24(4):195-203. PubMed ID: 24557078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.
    Kim KA; Joo HJ; Lee HM; Park JY
    Pharmacogenet Genomics; 2014 Jan; 24(1):35-42. PubMed ID: 24240480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.